IN8BIO, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M |
| Operating expenses | $19.9M | $30.7M | $30.3M | $28.5M | $14.7M |
| Cash from operations | -$12.7M | -$24.1M | -$23.3M | -$24.1M | -$13.5M |
| Capital expenditure | — | — | $0 | $356,000 | $0 |
| Free cash flow | — | — | -$23.3M | -$24.5M | -$13.5M |
| Total assets | $32.3M | $20.9M | $33.7M | $33.0M | $42.2M |
| Total liabilities | $4.7M | $6.5M | $8.8M | $10.3M | $4.0M |
Shares outstanding 9.8M · Free float 74.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.